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Summary--LNCaP cells (derived from a lymph node carcinoma of the human prostate) show 
androgen responsive growth. Progestagens, estradiol and antiandrogens competed with 
androgens for binding to the androgen receptor in the cells to a higher extent han in other 
androgen-sensitive systems. Optimal growth (3-4 fold increase in DNA content of 6 day cell 
cultures vs controls) was observed after addition of the synthetic androgen R1881 (0.1 nM). 
Both steroidal and non-steroidal ntiandrogens did not suppress the androgen responsive 
growth. At a concentration of l0 nM cyproterone acetate or 100 nM RU 23908, growth was 
even stimulated to an extent comparable to that observed after addition of androgen. 
Cyproterone acetate and RU 23908 also increased the number of epidermal growth factor 
receptors expressed at the cell surface to a comparable l vel as did the androgen. Like 
androgens, cyproterone acetate, RU 23908 or estradiol stimulated the secretion per cell of 
prostate specific acid phosphatase in the culture fluid. In conclusion, antiandrogens can exert 
striking stimulatory effects on the proliferation of LNCaP cells probably due to a defective 
androgen receptor system. It is discussed that comparable changes in the specificity of the 
androgen receptor in prostate cancer cells may give these cells an advantage in growth rate 
and may contribute to development of tumors characterized ashormone independent. 
INTRODUCTION 
Among the six permanent growing human 
prostate cell lines described up to now [1] only 
the LNCaP (lymph node carcinoma of the 
prostate) cell line developed by Horoszewicz et 
al. [2] shows androgen dependent growth [2-5]. 
This increase in growth rate is not due to 
neutralization of serum factors as has recently 
been suggested [6]; an increase in growth rate 
by androgens is also seen in growth factor 
inactivated or serum-free medium [7]. LNCaP 
cells contain considerable amounts of androgen 
receptors while estrogen and progestagen recep- 
tors are not detectable. However, estrogens and 
progestagens compete for binding to the andro- 
gen receptor in LNCaP cells and have stimu- 
latory effects on growth of the cells [5]. 
In the present study the effects of a steroidal 
(cyproterone acetate) and non-steroidal (RU 
23908) antiandrogen on LNCaP cell prolifer- 
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ation, secretion of PAP and expression of EGF 
receptors were investigated. We demonstrate 
that these androgen-dependent processes were 
stimulated by antiandrogens. 
EXPERIMENTAL 
Materials 
[3H]RI881 (methyltrienolone, 87Ci/mmol), 
radioinert R1881 and R5020 were purchased 
from New England Nuclear (Boston, MA). 
Cyproterone acetate was a gift from Schering 
(Berlin, F.R.G.). RU 23908 (anandron) was 
a gift from Roussel Uclaf (Paris, France). 
Triamcinolone acetonide was obtained from 
Sigma, U.S. Mouse '25I labeled EGF (140 Ci/g, 
Amersham) was used following removal of free 
iodine by Sephadex G25 gelfiltration. 
Tumor cells 
The LNCaP cell line was a gift of Dr 
Horoszewicz [2]. Cells were cultured and growth 
characteristics were analyzed as described 
previously[5]. The PC-EW human prostate 
tumor [8], grown in a nude mouse, was kindly 
provided by Dr van Steenbrugge. 
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Steroid and EGF binding studies 
Cytosol of LNCaP cells was prepared and 
competition studies with steroids were per- 
formed as described before [5, 9]. EGF binding 
to LNCaP cell monolayers was studied as 
reported before [5]. 
Assay of prostate specific acid phosphatase 
The concentration of prostate specific acid 
phosphatase in culture fluid was assayed 
immunologically with a commercially available 
test kit (Enzygnost PAP) from Behring Diag- 
nostica according to the recommendations of 
the supplier. The limit of detection was 0.2 #g 
enzyme/l. The antibodies of this kit do not cross 
react with other acid phosphatase isoenzymes. 
RESULTS 
Effects of androgen and antiandrogens ongrowth 
of LNCaP cells 
LNCaP cells were cultured for 6 days in 
medium containing 5% (v/v) charcoal treated 
fetal calf serum and various concentrations of
different compounds. At day 6, DNA content 
per culture was determined (Fig. 1). The syn- 
thetic, non-metabolizable androgen R1881 was 
used for study of growth stimulatory effects. In 
LNCaP cells the effects of R1881 are mediated 
by the androgen receptor because progestagen 
receptors are absent in these cells[5]. R1881 
stimulated growth maximally at a concentration 
of 0.1 nM (3-4 fold increase in DNA content 
per culture vs control cultures). As observed 
before [5] stimulation at higher concentration of
R1881 is limited. Cyproterone acetate stimu- 
lated cell growth twofold at 10 nM while at this 
concentration RU 23908 had no effect. At a 
concentration of 100mM, both cyproterone 
acetate and RU 23908 stimulated LNCaP cell 
proliferation to the same extent as 0.1 nM 
R1881. When 0.1 nM RI881 was added to the 
cell cultures in combination with 100nM 
cyproterone acetate or 100nM RU 23908, 
growth stimulation was similar as observed for 
R1881 or antiandrogens added alone (Fig. 1). 
The synthetic glucocorticoid triamcinolone 
acetonide did not affect growth at concen- 
trations up to I/~M. 
In a separate series of experiments he effect 
of long-term cyproterone acetate treatment was 
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Fig. I. Effects of various concentrations of R1881, cyproterone acetate (CA), anandron (RU 23908) and 
triamcinolone acetonide (TA) on growth of LNCaP cells after 6 days treatment with indicated compounds. 
Growth is expressed as mean DNA content per culture relative to control cultures (--). Shaded bars 
show the effect of indicated antiandrogen plus 0.1 nM R 1881. Standard eviations of triplicate xperiments 
are shown. 
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Table 1. Relative binding affinity (RBA) of different 
ligands for the androgen receptor in LNCaP cells and 
PC-EW tumor 
RBA value 
Ligand LNCaP PC-EW 
RI881 100 100 
Dihydrotestosterone 88 83 
Progesterone 17 0.3 
Cyproterone acetate 12.5 - -  
R5020 8.4 0.3 
Estradiol 2.4 0.2 
Ru 23908 1.0 - -  
Triamcinolone acetonide < 0.1 < 0.1 
--,  Not determined. 
studied. Continuous timulation was observed 
for 42 days by both R1881 and cyproterone 
acetate compared to controls. 
Androgen receptor binding 
The binding specificity of the androgen recep- 
tor was measured by incubating cytosol of 
LNCaP cells or PC-EW tumors with 5nM 
[3H]RI881 in the presence of various concen- 
trations of steroids and antiandrogens. Relative 
binding a~nity (RBA) values were calculated 
from competitive binding curves [9] as the ratio 
of concentration of unlabeled compound and 
concentration of R1881 required to inhibit 
[3H]R1881 binding by 50% (Table 1). The RBA 
value of R1881 was set at 100. In LNCaP cells 
the affinities of the receptor for both progester- 
one and R5020 (a synthetic, non-metabolizable 
Table 2. Effect of different compounds on EGF binding to LNCaP 
cells 
Condition Bound (fmol EGF/mg DNA) 
Control 495 + 20 
100 nM triamcinolone acetonide 480 + 25 
0.1 nM R1881 720+25 
100 nM cyproterone acetate 745 + 10 
100 nM RU 23908 690 + 10 
progestagen), were much higher than in the 
transplantable prostate tumor PC-EW. In 
addition, the receptor obtained from the 
LNCaP cells showed considerable affinity for 
estradiol, cyproterone acetate and RU 23908. 
Induction of EGF receptors 
Previous studies demonstrated that andro- 
gens increase both growth rate and EGF recep- 
tor activity in LNCaP cells [7]. EGF binding to 
LNCaP cell monolayers was measured after 24 h 
treatment with various compounds (Table 2). 
Both antiandrogens (100 mM) increased EGF 
binding to LNCaP cells to a level comparable to
the binding obtained after addition of R1881 
(0. l nM). Triamcinolone acetonide had no effect 
on EGF binding to LNCaP cells. 
Secretion of prostate specific acid phosphatase 
The time course of secretion of prostate acid 
phosphatase (PAP) in the culture fluid is shown 
in Fig. 2. PAP secretion in the culture fluid 
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Fig. 2. Growth curves (panel A) and time course of secretion (panel B) of prostate specific acid 
phosphatase by LNCaP cells. Cells were cultured in the absence (O- -O)  or presence of following 
compounds: 0.1 nM R1881 (m- - -B ) ,  100 nM cyproterone acetate (©- -©) ,  100 nM RU 23908 (A - -A)  
or I00 nM triamcinolone acetonide (D- - - I - l ) .  
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was calculated and expressed per 100/~g DNA 
in order to correct for differences between 
cell numbers in control and hormone treated 
cultures. R1881 and cyproterone acetate were 
the most potent stimulators of PAP secretion; a
3-4 fold increase after 6 days vs control cells 
was observed. RU 23908 doubled PAP secretion 
compared to controls. For control cells and 
cells treated with triamcinolone acetonide the 
amount of PAP secreted remained constant 
after 3 days. We previously reported that 10 nM 
estradiol also stimulated cell growth [5]. Treat- 
ment of LNCaP cells with 10nM estradiol 
increased PAP secretion to the same extent as 
observed after addition of 0.1 nM R1881 (64 #g 
PAP/100 #g DNA at day 6). 
DISCUSSION 
The biological effects of a steroidal and a 
non-steroidal antiandrogen on LNCaP human 
prostate tumor cells were compared with effects 
of the androgen R1881. In contrast to our 
expectation both cyproterone acetate and RU 
23908 exerted striking stimulatory effects on 
LNCaP cell proliferation. Recently, similar 
results have been obtained by Wilding et aL [10], 
who showed agonistic effects of hydroxy- 
flutamide, RU 23908 and cyproterone acetate 
with respect to growth rate and thymidine incor- 
poration by LNCaP cells. In a preliminary study 
from our laboratory[4] stimulatory effects of 
cyproterone acetate were not seen when cells 
were cultured in 15% fetal calf serum. Removal 
of endogenous steroids from the culture 
medium (by charcoal stripping) is essential 
for study of the effect of added steroids on 
biological characteristics of the cells. 
In short-term cultures of human prostatic 
tissues an enhanced production of PAP can be 
observed in response to physiological levels of 
testosterone and dihydrotestosterone [11]. 
R1881 is the most effective stimulator of PAP 
expression in LNCaP cells [3]. This may be 
explained by the facts that R1881 firmly binds 
to androgen receptors and is only slowly, if at 
all, decomposed to inactive products in prostate 
tissue, in contrast o testosterone and dihydro- 
testosterone. Schulz et al. [3] showed that estro- 
gens but not triamcinolone acetonide can 
increase PAP secretion in the culture fluid. We 
confirm these observations and showed that also 
antiandrogens timulated PAP secretion by 
LNCaP cells. Estradiol and cyproterone acetate 
were more potent than RU 23908: the differ-. 
ences in stimulatory effect reflected the variation 
in relative binding affinity to the androgen 
receptor. 
EGF can stimulate the growth of LNCaP 
cells and androgens increase the number of 
EGF receptors expressed at the cell surface [7]. 
EGF acts synergistically with androgen on 
LNCaP cells to induce cell proliferation, prob- 
ably due to up-regulation of EGF receptors by 
androgen [12]. The antiandrogens also exerted 
stimulatory effects with respect o induction of 
EGF receptors in LNCaP cells. Both cypro- 
terone acetate and RU 23908 increased EGF 
receptor levels. 
Cytosolic fractions of LNCaP cells and PC- 
EW transplantable prostate tumor tissue differ 
with respect to the binding specificity of the 
androgen receptor. The receptor in LNCaP cells 
has a broad specificity and binds in addition to 
androgens especially progestagens with high 
affinity. Cyproterone acetate and RU 23908 
compete with androgens for androgen binding 
sites in LNCaP cells. RU 23908 binds only to 
androgen receptors while R1881 and cypro- 
terone acetate show considerable affinity for 
progestin receptors [13]. However, the effects of 
the two latter ligands are entirely mediated via 
the androgen receptor since progesterone r cep- 
tors are absent in LNCaP cells [5]. Cyproterone 
acetate shows a higher affinity for androgen 
receptors than RU 23908113], in agreement 
with the observation that cyproterone acetate 
stimulates growth of LNCaP cells at a lower 
concentration than RU 23908. 
Since the LNCaP cell line is the only in v i t ro 
growing androgen-responsive prostate tumor 
system of human origin it is not possible to 
investigate if loss of proper response to antian- 
drogens by metastatic prostate tumor cells is a 
general phenomenon for this type of cells in 
culture. However, it was recently communicated 
(S. E. Harris et al., J. Trapman et al., unpub- 
lished studies) that the androgen receptor in 
LNCaP cells contains a mutation at aminoacid 
877 (thr to ala) in the C-terminal part of the 
steroid binding domain. The mutation is in an 
essential conserved region of the steroid binding 
domain of the receptor. At the similar position 
in the glucocorticoid receptor a cysteine (cys 
754) can be covalently linked to the glucocorti- 
coid triamcinolone acetonide by photo-affinity 
labeling [14]. One of the mechanisms by which 
antihormones might antagonize steroid hor- 
mones at the molecular level is at the level of 
transcription. Upon binding of the antihormone 
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to the receptor, this complex binds to hormone 
responsive elements of DNA but fails to induce 
the transcription activation function. This tran- 
scription activation function is probably located 
in the steroid hormone binding domain of the 
receptor [15, 16]. It is tempting to speculate that 
the mutation in the steroid binding domain of 
the androgen receptor of LNCaP cells makes it 
possible for antiandrogens and for different 
steroids (progestagens, estrogens) to activate 
this transcription activation function. 
The results of the present study imply that 
further studies on tumor samples obtained from 
prostate carcinoma re needed to investigate he 
cause of an unfavorable response to hormonal 
therapy. In vivo in advanced metastatic prostate 
cancer the tumors may pass through a stage in 
which they are stimulated by antiandrogens or 
estrogens. 
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